Earnings Summary

Acelrx Pharmaceuticals, Inc.’s revenue fell -76.92% since last year same period to $0.12Mn in the Q3 2023. On a quarterly growth basis, Acelrx Pharmaceuticals, Inc. has generated -53.75% fall in its revenue since last 3-months.

Acelrx Pharmaceuticals, Inc.’s net profit jumped 79.9% since last year same period to $-1.36Mn in the Q3 2023. On a quarterly growth basis, Acelrx Pharmaceuticals, Inc. has generated 68.95% jump in its net profits since last 3-months.

Acelrx Pharmaceuticals, Inc.’s net profit margin jumped 12.88% since last year same period to -1159.83% in the Q3 2023. On a quarterly growth basis, Acelrx Pharmaceuticals, Inc. has generated 32.87% jump in its net profit margins since last 3-months.

Acelrx Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.18 - a 35.71% jump from last quarter’s estimates.

Acelrx Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -0.18.

Acelrx Pharmaceuticals, Inc.’s earning per share (EPS) jumped 91.49% since last year same period to -0.08 in the Q3 2023. This indicates that the Acelrx Pharmaceuticals, Inc. has generated 91.49% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Acelrx Pharmaceuticals, Inc.’s return on assets (ROA) stands at -0.32.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Acelrx Pharmaceuticals, Inc.’s return on equity (ROE) stands at -0.51.